Holen Sie sich die Stockscreener-App
202.83
0.32%
-0.66
Handel nachbörslich:
205.00
2.17
+1.07%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.
AstraZeneca stock gains 1.77% as strong oncology-driven revenue and earnings growth boosts sentiment - Traders Union
Perpetual Ltd Has $515,000 Stock Holdings in Astrazeneca Plc $AZN - marketbeat.com
Astrazeneca Plc $AZN Stock Holdings Lowered by Cidel Asset Management Inc. - marketbeat.com
AstraZeneca reports positive EMERALD-3 results for HCC - Clinical Trials Arena
AstraZeneca PLC (AZN) Stock Price, News, Quote & History - Yahoo! Finance Canada
AstraZeneca PLC (AZN.L) Stock Price, News, Quote & History - Yahoo! Finance Canada
AstraZeneca PLC (AZN.L) stock price, news, quote and history - Yahoo Finance UK
AstraZeneca: The Bigger Picture Remains Solid Growth Amidst Improving Margins And Returns - Seeking Alpha
Aberdeen Group plc Grows Stake in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca (NYSE:AZN) Cut to Hold at Wall Street Zen - MarketBeat
FTSE AstraZeneca PLC Index (SSAZNS.FGI) Forum & Discussion - Yahoo! Finance Canada
AstraZeneca stock gains 1.77% as bullish technicals and positive trial results fuel buying - Traders Union
AstraZeneca PLC stock: Positive liver cancer trial results spark investor interest - AD HOC NEWS
AZN Stock Quote Price and Forecast - CNN
AstraZeneca (AZN) Faces New Tariff Challenges Amid U.S. Import D - GuruFocus
AstraZeneca’s New Cancer Combo Trial Signals Steady Progress in Antibody Drug Conjugates - TipRanks
AstraZeneca climbs Thursday, outperforms market - MarketWatch
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,500 GBp From 16,000 GBp - Insider Monkey
AstraZeneca reports positive phase III results for Imfinzi and Imjudo in liver cancer - Investing.com
AstraZeneca (NYSE: AZN) liver cancer combo boosts PFS in Phase III - Stock Titan
AstraZeneca PLCImfinzi+Imjudo improves PFS in early liver cancer - Research Tree
AstraZeneca’s Liver Cancer Treatment Shows Promise in Phase III Trial - AskTraders
AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial - Reuters
AstraZeneca (AZN) Sees Success in EMERALD-3 Trial for Liver Canc - GuruFocus
ASTRAZENECA : Buy rating from JP Morgan - MarketScreener
Pictet North America Advisors SA Has $8.54 Million Stock Holdings in Astrazeneca Plc $AZN - marketbeat.com
Astrazeneca plc Announces Positive High-Level Results from the Emerald-3 Phase III Trial - marketscreener.com
AstraZeneca hails encouraging data for liver cancer drug regimen - London South East
AstraZeneca upbeat on results of liver cancer treatment trial - sharecast.com
AstraZeneca Says Liver Cancer Drug Combination Extends Progression-Free Survival in Phase 3 Trial - marketscreener.com
AstraZeneca Reports Positive Phase III EMERALD-3 Results In Unresectable Liver Cancer - DirectorsTalk Interviews
Deutsche Bank Maintains Sell on AstraZeneca (AZN) - Insider Monkey
Nordic Stocks in North AmericaAstraZeneca Gains 1.8 Percent - MarketScreener
Cowen Maintains Buy on AstraZeneca PLC (AZN) March 18, 2026 - Meyka
AstraZeneca PLC Stock: Institutional Confidence Builds as Voting Rights Update Signals Stability for - AD HOC NEWS
AstraZeneca PLC Stock Gains Momentum on Positive Tozorakimab Phase 3 Data for COPD Treatment - AD HOC NEWS
Strong clinical milestones drive AstraZeneca stock higher despite mixed momentum readings - Traders Union
AstraZeneca updates total voting rights following admission of new shares - Investing.com
AstraZeneca (NYSE: AZN) updates voting rights and admits new shares - Stock Titan
AstraZeneca PLC Stock (AZN) Moved Up by 3.43% on Apr 1: Facts Behind the Movement - TradingKey
US bank sees AstraZeneca HPP drug data as supportive of $2.6bn forecast with upside to $4.4bn despite mixed trial results - Proactive financial news
AstraZeneca reports positive data from Phase III trial of efzimfotase alfa - Clinical Trials Arena
Moody Lynn & Lieberson LLC Increases Holdings in Astrazeneca Plc $AZN - marketbeat.com
Morgan Stanley sees double-digit EPS growth for AstraZeneca PLC (AZN) - MSN
What's Going On With AstraZeneca Stock Tuesday?AstraZeneca (NYSE:AZN) - Benzinga
AstraZeneca PLC Stock (AZN) Opened Up by 3.38% on Mar 31: Drivers Behind the Movement - TradingKey
AstraZeneca’s ALXN1850 On Blockbuster Trajectory Despite Mixed Phase III Results - Citeline News & Insights
Astrazeneca reports positive phase III results for efzimfotase alfa in hypophosphatasia - Investing.com
ASTRAZENECA : Buy rating from Barclays - MarketScreener
AstraZeneca (AZN) Reports Positive Results from HPP Clinical Tri - GuruFocus
[6-K] ASTRAZENECA PLC Current Report (Foreign Issuer) | AZN SEC FilingForm 6-K - Stock Titan
AstraZeneca PLC (AZN) Stock Price, Trades & News - GuruFocus
ASTRAZENECA : JP Morgan maintains a Buy rating - MarketScreener
Eyes on Asia: Otsuka, Biogen, AstraZeneca - bioxconomy.com
ASTRAZENECA : Buy rating from Jefferies - MarketScreener
AstraZeneca says hypophosphatasia replacement enzyme trials positive - London South East
Boston Common Asset Management LLC Increases Stock Holdings in Astrazeneca Plc $AZN - marketbeat.com
AstraZeneca drug for rare bone disease shows positive trial results - Sharecast.com
ASTRAZENECA : Barclays remains its Buy rating - MarketScreener
Astrazeneca Plc $AZN Shares Bought by Allspring Global Investments Holdings LLC - marketbeat.com
AstraZeneca PLC Stock: Positive Tozorakimab COPD Trial Results Drive Shares Higher Amid Strong Pipel - AD HOC NEWS
AZN Technical Analysis | Trend, Signals & Chart Patterns | ASTRAZENECA PLC-SPONS ADR (NYSE:AZN) - ChartMill
Efzimfotase alfa demonstrated positive results from global Phase III clinical programme in hypophosphatasia - AstraZeneca
0.02%
0.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):